%0 Journal Article
%T Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
%A Chao Zhang
%A Chenglan Zhang
%A Jianyu Zheng
%A Mei Cao
%A Qingxiang Guo
%A Rong Xiang
%A Shengyong Yang
%A Tianqi Wang
%A Wei Zhou
%A Wenzhi Shen
%A Xin Wang
%A Yakun Ma
%A Yan Fan
%A Yanan Chen
%A Yanhua Liu
%A Yongtao Li
%A Zhi Huang
%J Theranostics
%D 2018
%I Ivyspring International Publisher
%R 10.7150/thno.26627
%X Despite initial progress in preclinical models, most known histone deacetylase inhibitors (HDACis) used as a single agent have failed to show clinical benefits in nearly all types of solid tumours. Hence, the efficacy of HDACis in solid tumours remains uncertain. Herein, we developed a hybrid HDAC inhibitor that sensitized solid tumours to HDAC-targeted treatment.
%K HDAC1
%K CDK4/6
%K JAK1
%K inhibitor
%K solid tumour
%U http://www.thno.org/v08p4995.htm